TP53 and pancreatic ductal adenocarcinoma: Moreover, we have previously reported that OBP-702, the p53-armed OV, significantly increased the release of immunologic molecules compared with OBP-301, the non-armed OV, via stronger p53-mediated apoptosis and autophagy in pancreatic ductal adenocarcinoma cells.33